Table 1 Baseline characteristics and improvement at M1 in the explorative and validation datasets.

Explorative set (n = 261)

Validation set (n = 111)

p value

Female (%)^a

41.4

37.8

0.524

Age of onset (yr)

53.3 ± 9.5

54.3 ± 9.4

0.311

Disease duration (yr)

8.9 ± 4.7

9.0 ± 5.6

0.955

Age at surgery (yr)

62.9 ± 8.5

63.9 ± 7.7

0.276

TD/PIGD/MX^a

96/135/30

37/59/15

0.758

TD/AR/MX^a

45/167/49

20/63/28

0.325

History of fall^a

51.2%

49.5%

0.093

History of festinating gait^a

76.2%

72.1%

0.395

Hoehn-Yahr stage (1/2/3/4/5)^b

3/51/188/14/5

2/24/75/7/3

0.358

UPDRS-II

21.1 ± 7.7

20.5 ± 7.0

0.549

UPDRS-III ON

26.9 ± 14.4

27.9 ± 14.7

0.548

UPDRS-III OFF

53.7 ± 18.5

56.2 ± 20.7

0.248

UPDRS-III levodopa response (%)

50.7 ± 18.0

50.8 ± 17.3

0.989

BBS ON

49.4 ± 6.4

51.0 ± 4.8

0.016

BBS OFF

40.0 ± 12.0

41.3 ± 11.6

0.347

BBS levodopa response (%)

20.8 ± 21.8

18.6 ± 19.7

0.361

PT ON (0/1/2/3/4)^b

94/118/34/10/5

43/53/13/2/0

0.158

PT OFF (0/1/2/3/4)^b

17/81/87/58/18

11/31/40/25/4

0.258

LEDD

809.9 ± 588.8

766.6 ± 334.0

0.469

FOG-Q

13.5 ± 8.3

13.0 ± 8.0

0.601

PDQ-39

54.9 ± 22.0

51.6 ± 23.3

0.191

MMSE

26.2 ± 3.7

26.3 ± 3.6

0.783

MoCA

20.8 ± 5.2

20.4 ± 5.1

0.392

UPDRS-III M1 change rate

36.8 ± 27.4%

34.7 ± 27.4%

0.215

BBS M1 change rate

14.8 ± 21.9%

13.3 ± 21.3%

0.346

PT M1 mean difference^b

0.8 ± 1.0

0.8 ± 1.1

0.445